Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy-Reference-Cited by-同舟云学术

Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy

Published:2023-09-28 Issue:8 Volume:58 Page:842-844
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Su Jia‐Yong¹,Wu Ying‐Ling¹,Wu Xuan‐Lin¹,Liu Zhen‐Xiu¹,Wang Yi‐Yang¹,Li Zhong‐Hai¹,Luo Jia‐Xin¹,Wu Kun‐Jun¹,Zhong Jian‐Hong¹²³^ORCID

Affiliation:

1. Hepatobiliary Surgery Department Guangxi Medical University Cancer Hospital Nanning China

2. Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University) Ministry of Education Nanning China

3. Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor Nanning China

Abstract

LINKED CONTENTThis article is linked to Ogawa et al papers. To view these articles, visit https://doi.org/10.1111/apt.17107 and https://doi.org/10.1111/apt.17693.

Funder

Specific Research Project of Guangxi for Research Bases and Talents

Guangxi Medical University

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17668

Reference8 articles.

1. Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

2. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers

3. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China

4. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis

5. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma;Computational and Structural Biotechnology Journal;2024-12

2. Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions;Journal of Clinical and Translational Hepatology;2024-04-24

3. Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomy—Author's reply;Alimentary Pharmacology & Therapeutics;2023-09-28